提供高价值的癌症护理：欧洲癌症不平等登记分析报告

European Cancer Inequalities Registry Analytical Report Delivering High ValueCancer Care EUROPEAN CANCER INEQUALITIES REGISTRYANALYTICAL REPORT This work is published under the responsibility of the Secretary-General of the OECD and the President of the European Commission.The opinions expressed and arguments employed herein do not necessarily reflect the official views of the OECD Member countries orof the European Union. The names of countries and territories and maps used in this joint publication follow the practice of the OECD. This document, as well as any data and map included herein, are without prejudice to the status of or sovereignty over any territory, tothe delimitation of international frontiers and boundaries and to the name of any territory, city or area. Specific territorial disclaimers applicable to the OECD: The statistical data for Israel are supplied by and under the responsibility of the relevant Israeli authorities. The use of such data by theOECD is without prejudice to the status of the Golan Heights, East Jerusalem and Israeli settlements in the West Bank under the termsof international law. Note by the Republic of Türkiye The information in this document with reference to “Cyprus” relates to the southern part of the Island. There is no single authorityrepresenting both Turkish and Greek Cypriot people on the Island. Türkiye recognises the Turkish Republic of Northern Cyprus(TRNC). Until a lasting and equitable solution is found within the context of the United Nations, Türkiye shall preserve its positionconcerning the “Cyprus issue”. Note by all the European Union Member States of the OECD and the European UnionThe Republic of Cyprus is recognised by all members of the United Nations with the exception of Türkiye. The information in thisdocument relates to the area under the effective control of the Government of the Republic of Cyprus. Please cite this publication as: OECD/European Commission (2026),Delivering High Value Cancer Care: European Cancer Inequalities Registry Analytical Report, OECDPublishing, Paris, https://doi.org/10.1787/060869fe-en. ISBN 978-92-64-69820-8 (print)ISBN 978-92-64-77628-9 (PDF)ISBN 978-92-64-87303-2 (HTML) European UnionISBN 978-92-68-36308-9 (print)ISBN 978-92-68-36303-4 (PDF)Catalogue number: EW-01-26-012-EN-C (print)Catalogue number: EW-01-26-012-EN-N (PDF) Photo credits:Cover © SeventyFour/Shutterstock.com. Corrigenda to OECD publications may be found at: https://www.oecd.org/en/publications/support/corrigenda.html.© OECD/European Union 2026. Attribution 4.0 International (CC BY 4.0) This work is made available under the Creative Commons Attribution 4.0 International licence. By using this work, you accept to be bound by the terms of this licence(https://creativecommons.org/licenses/by/4.0/).Attribution– you must cite the work. Translations– you must cite the original work, identify changes to the original and add the following text:In the event of any discrepancy between the original work and thetranslation, only the text of original work should be considered valid. Adaptations– you must cite the original work and add the following text:This is an adaptation of an original work by the OECD and the European Union. The opinions expressed andarguments employed in this adaptation should not be reported as representing the official views of the OECD, its Member countries or the European Union. You must not use the OECD’s or the European Commission's respective logo, visual identity or cover image without express permission or suggest the OECD or the EuropeanCommission endorse your use of the work. Any dispute arising under this licence shall be settled by arbitration in accordance with the Permanent Court of Arbitration (PCA) Arbitration Rules 2012. The seat of arbitration shallbe Paris (France). The number of arbitrators shall be one. Foreword Cancer remainsoneof the most significant public health challenges. It is the second-leading cause ofdeath in EU countries, and the rising number of cancer cases–now increasingly affecting people under50–poses a growing social and economic burden. Diagnosis at youngerages means longer treatment andmonitoring for patients, placing sustained pressure on healthcare systems and affecting patients’ well-being andsocio-economicsituation for many years. By 2050, the EU27 will face markedly higher demandfor cancer care, with population ageing driving an estimated59% rise in real per-capita cancer spending.This surge is occurring at a time when public budgets are already strained by competing priorities andeconomic uncertainty. Ensuring that cancer care delivers clear value for patients and health systems isessential. Delivering High Value Cancer Careprovides cross-country comparable data and policy perspectives onthreepressing priorities to ensure high-value cancer care that contributes to health outcomes and people’squalityof life:timely access to services,evidence-based and efficient care,and